In February 2026, investor interest in SME IPOs remained selective, with attention centred on companies operating in niche manufacturing and specialty segments. Businesses involved in specialty chemicals continued to attract interest due to their diversified end use industries, relatively higher margins, and growing demand from organised sectors such as textiles, home care, and agriculture.
Against this backdrop, Biopol Chemicals Limited is set to open its IPO on February 6, 2026. Here is a detailed overview of Biopol Chemicals Limited, its IPO, and the industry outlook.
About Biopol Chemicals Ltd.
Incorporated in 2023, Biopol Chemicals Limited is engaged in the manufacturing and distribution of specialty chemicals categorised into silicones, emulsifiers, biochemicals, and polyelectrolytes. The company operates on a business to business model, catering primarily to institutional and industrial clients.
The company has a diversified product portfolio comprising 66 products, including 40 silicone based products, 5 emulsifier based products, 15 biochemical products, and 6 polyelectrolyte products. These products find applications across multiple industries such as textiles, home care, agriculture, and industrial chemicals.
Biopol Chemicals operates through four establishments located in Gujarat and West Bengal. These include its manufacturing unit, corporate office, and warehouse in West Bengal, along with its registered office in Gujarat. The manufacturing facility has an installed capacity of 18,25,000 litres per annum. As on December 31, 2025, the company employed 24 people and also reported export operations to Bangladesh.
Product Portfolio
• Textile Chemicals including softeners, silicones, emulsions, hydrophilic finishes, hardeners and binders, dyeing and printing auxiliaries
• Home Care products such as silicone fluids, emulsifiers, and cleaning chemicals
• Agriculture chemicals including silicone adjuvants and surfactants
• Industrial Chemicals such as silicone based release agents and specialty lubricants for PVC
Biopol Chemicals Ltd. IPO Details
Biopol Chemicals IPO is a book build issue of ₹31.26 crores. The issue is entirely a fresh issue of 0.29 crore shares aggregating to ₹31.26 crores. The IPO price band has been fixed at ₹102 to ₹108 per share, and the issue is proposed to be listed on NSE SME.
The company intends to utilise the net proceeds from the issue towards acquisition of industrial land, repayment or prepayment of borrowings, and general corporate purposes.
Important IPO Timeline
| Event | Date |
|---|---|
| IPO Open Date | February 6, 2026 |
| IPO Close Date | February 10, 2026 |
| Allotment Date (Tentative) | February 11, 2026 |
| Initiation of Refunds | February 12, 2026 |
| Credit of Shares to Demat | February 12, 2026 |
| Listing Date (Tentative) | February 13, 2026 |
Key IPO Details
Here is the table on the Biopol Chemicals Ltd. IPO Review.
| Particulars | Details |
|---|---|
| Face Value | ₹10 per share |
| Issue Price Band | ₹102 to ₹108 per share |
| Lot Size | 1,200 shares |
| Total Issue Size | 28,94,400 shares aggregating up to ₹31.26 crore |
| Fresh Issue | 28,94,400 shares aggregating up to ₹31.26 crore |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Shareholding Pre Issue | 79,11,000 shares |
| Shareholding Post Issue | 1,08,05,400 shares |
| Market Capitalisation Pre IPO | ₹116.70 crore |
Lot Size of Biopol Chemicals Ltd. IPO
The table below outlines the lot size and investment amount for different categories of investors based on the upper price band.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Investor Min | 2 | 2,400 | ₹2,59,200 |
| Retail Investor Max | 2 | 2,400 | ₹2,59,200 |
| S HNI Min | 3 | 3,600 | ₹3,88,800 |
| S HNI Max | 7 | 8,400 | ₹9,07,200 |
| B HNI Min | 8 | 9,600 | ₹10,36,800 |
Biopol Chemicals Ltd. Financials
Biopol Chemicals IPO has a pre issue market capitalisation of ₹116.70 crore. As of December 31, 2025, the company reported strong profitability metrics with a Return on Equity of 36.32 percent and a Return on Capital Employed of 26.32 percent. The Return on Net Worth stood at 30.74 percent, while the Profit After Tax margin improved to 12.29 percent. EBITDA margin for the same period was reported at 18.41 percent.
Other financial details of the company are summarised below.
Key Company Financials
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 48.88 | 31.48 | 17.56 |
| Total Income | 48.97 | 49.15 | 17.43 |
| Profit After Tax | 6.00 | 4.33 | 2.96 |
| EBITDA | 8.99 | 6.53 | 4.43 |
| Net Worth | 19.54 | 13.53 | 9.20 |
| Reserves and Surplus | 11.63 | 5.62 | 1.29 |
| Total Borrowing | 14.92 | 7.69 | 3.58 |
Amount in ₹ crore.
Biopol Chemicals Ltd.: Industry Outlook
• Demand for specialty chemicals continues to rise across textiles, home care, agriculture, and industrial applications
• Silicone based and value added chemical products typically offer higher margins compared to commodity chemicals
• Growth in organised textile processing and home care manufacturing is supporting steady demand
• Export opportunities in neighbouring markets can provide incremental growth, though pricing and competition remain key factors
• The specialty chemicals segment remains competitive, with profitability dependent on product mix, scale, and cost control
Conclusion
Biopol Chemicals Ltd. presents an SME IPO opportunity for investors seeking exposure to the specialty chemicals segment with diversified end use industries. The company has demonstrated strong growth in revenues and profitability over recent periods and operates with a broad product portfolio catering to textiles, home care, agriculture, and industrial applications. The IPO proceeds are expected to support capacity related expansion through land acquisition, reduce leverage, and strengthen the balance sheet.
However, potential investors should carefully assess risks such as the sustainability of recent performance, competitive pressures in specialty chemicals, and execution risks associated with expansion plans. As with all SME IPOs, reviewing the offer documents in detail and aligning the investment with individual risk appetite remains essential.
